Since imatinib has been demonstrated to contribute to P-gp-mediated MDR in chronic myeloid leukemia (CML) K562 cell lines, administration of ketoconazole can suppress P-gp expression in CML cancer cell lines [153]. The gene discussed is PGP; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.